139 related articles for article (PubMed ID: 14512191)
1. Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer.
Keller SM; Vangel MG; Wagner H; Schiller J; Herskovic A; Komaki R; Gray R; Marks RS; Perry MC; Livingston RB; Johnson DH;
Lung Cancer; 2003 Oct; 42(1):79-86. PubMed ID: 14512191
[TBL] [Abstract][Full Text] [Related]
2. The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer.
Keller SM; Vangel MG; Adak S; Wagner H; Schiller JH; Herskovic A; Komaki R; Perry MC; Marks RS; Livingston RB; Johnson DH
Lung Cancer; 2002 Sep; 37(3):303-9. PubMed ID: 12234700
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
[TBL] [Abstract][Full Text] [Related]
4. A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734.
Perry MC; Kohman LJ; Bonner JA; Gu L; Wang X; Vokes EE; Green MR
Clin Lung Cancer; 2007 Jan; 8(4):268-72. PubMed ID: 17311692
[TBL] [Abstract][Full Text] [Related]
5. Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590.
Wakelee HA; Stephenson P; Keller SM; Wagner H; Herskovic A; Komaki R; Marks RS; Perry MC; Livingston RB; Johnson DH;
Lung Cancer; 2005 Jun; 48(3):389-97. PubMed ID: 15893008
[TBL] [Abstract][Full Text] [Related]
6. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705.
Bradley JD; Paulus R; Graham MV; Ettinger DS; Johnstone DW; Pilepich MV; Machtay M; Komaki R; Atkins J; Curran WJ;
J Clin Oncol; 2005 May; 23(15):3480-7. PubMed ID: 15908657
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group.
Keller SM; Adak S; Wagner H; Herskovic A; Komaki R; Brooks BJ; Perry MC; Livingston RB; Johnson DH
N Engl J Med; 2000 Oct; 343(17):1217-22. PubMed ID: 11071672
[TBL] [Abstract][Full Text] [Related]
9. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.
Scagliotti GV; Fossati R; Torri V; Crinò L; Giaccone G; Silvano G; Martelli M; Clerici M; Cognetti F; Tonato M;
J Natl Cancer Inst; 2003 Oct; 95(19):1453-61. PubMed ID: 14519751
[TBL] [Abstract][Full Text] [Related]
10. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.
Schiller JH; Adak S; Feins RH; Keller SM; Fry WA; Livingston RB; Hammond ME; Wolf B; Sabatini L; Jett J; Kohman L; Johnson DH
J Clin Oncol; 2001 Jan; 19(2):448-57. PubMed ID: 11208838
[TBL] [Abstract][Full Text] [Related]
11. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group.
Johnstone DW; Byhardt RW; Ettinger D; Scott CB
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):365-9. PubMed ID: 12243809
[TBL] [Abstract][Full Text] [Related]
12. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial.
Douillard JY; Rosell R; De Lena M; Riggi M; Hurteloup P; Mahe MA;
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):695-701. PubMed ID: 18439766
[TBL] [Abstract][Full Text] [Related]
13. The risk of second primary tumors in patients with nasopharyngeal carcinoma after definitive radiotherapy.
Kong L; Lu JJ; Hu C; Guo X; Wu Y; Zhang Y
Cancer; 2006 Sep; 107(6):1287-93. PubMed ID: 16909425
[TBL] [Abstract][Full Text] [Related]
14. Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: long-term results of a phase II trial.
Eberhardt W; Stamatis G; Stuschke M; Wilke H; Müller MR; Kolks S; Flasshove M; Schütte J; Stahl M; Schlenger L; Budach V; Greschuchna D; Stüben G; Teschler H; Sack H; Seeber S
Br J Cancer; 1999 Dec; 81(7):1206-12. PubMed ID: 10584883
[TBL] [Abstract][Full Text] [Related]
15. Long-term evaluation of intrapleural bacillus Calmette-Guerin with or without adjuvant chemotherapy in completely resected stages II and III non-small-cell lung cancer.
Macchiarini P; Hardin M; Angeletti CA
Am J Clin Oncol; 1991 Aug; 14(4):291-7. PubMed ID: 1650528
[TBL] [Abstract][Full Text] [Related]
16. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
Sher DJ; Koshy M; Liptay MJ; Fidler MJ
Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II-IIIA non-small cell lung cancer: study protocol for a randomized controlled trial.
Saka H; Kitagawa C; Ichinose Y; Takenoyama M; Ibata H; Kato T; Takami K; Yamashita M; Maeda T; Takeo S; Ueda H; Okabayashi K; Nagashima S; Oka T; Kouso H; Fukuyama S; Yoshimoto K; Shimokawa M; Saito AM; Ito S
Trials; 2017 Sep; 18(1):429. PubMed ID: 28915900
[TBL] [Abstract][Full Text] [Related]
18. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.
Dillman RO; Herndon J; Seagren SL; Eaton WL; Green MR
J Natl Cancer Inst; 1996 Sep; 88(17):1210-5. PubMed ID: 8780630
[TBL] [Abstract][Full Text] [Related]
19. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
Bunn PA
Clin Lung Cancer; 2004 Sep; 6(2):85-98. PubMed ID: 15476594
[TBL] [Abstract][Full Text] [Related]
20. Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer.
Johnson BE; Rabin MS
Clin Cancer Res; 2005 Jul; 11(13 Pt 2):5022s-5026s. PubMed ID: 16000607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
